AIDS and Behavior

, Volume 20, Issue 11, pp 2674–2681 | Cite as

Correlates of Combination Antiretroviral Adherence Among Recently Diagnosed Older HIV-Infected Adults Between 50 and 64 years

  • Winston E. Abara
  • Oluwatoyosi A. Adekeye
  • Junjun Xu
  • Harry J. Heiman
  • George Rust
Original Paper


Optimal adherence to combination antiretroviral therapy is essential to the health of older people living with HIV (PLWH), however, the literature on adherence and aging is limited. Using Medicaid data from 29 states (N = 5177), we explored correlates of optimal adherence among older PLWH. The prevalence of optimal adherence was low (32 %) in this study. Males were more adherent than females (APR = 1.11, 95 % CI 1.02–1.21, P = 0.0127); persons with three or more co-morbidities (APR = 0.67, 95 % CI 0.60–0.74, P < 0.001), two co-morbidities (APR = 0.86, 95 % CI 0.75–0.98, P = 0.0319) and one co-morbidity (APR = 0.82, 95 % CI 0.73–0.92, P = 0.0008) were less adherent than those without any co-morbidity; and residents of rural areas (APR = 0.90, 95 % CI 0.63–0.98, P = 0.0385) and small metropolitan areas (APR = 0.82, 95 % CI 0.72–0.94, P = 0.0032) were less adherent than residents of large metropolitan areas. There were no racial differences in optimal adherence. Targeted interventions that provide adherence support, case management, and peer navigation services may be of benefit in achieving optimal adherence in this population.


HIV/AIDS Antiretroviral adherence People living with HIV Older adults Aging 


Alcanzar una óptima adherencia a la terapia antiretroviral es esencial para mantener la salud de adultos mayores viviendo con VIH (PVVIH). Sin embargo, hay una escasez de estudios enfocados en adherencia en adultos mayores. Usando datos de Medicaid provenientes de 29 estados, exploramos factores que afectan la adherencia en PVVIH que son adultos mayores. La prevalencia de adherencia óptima fue baja (32 %) entre los 5177 participantes. Los hombres fueron más adherentes que las mujeres [razón de prevalencia ajustada (RPA) = 1.11, 95 % intervalo de confianza (IC) = 1.02–1.21, P = 0.0127]; mientras que personas con tres o más comorbilidades (RPA = 0.67, 95 % IC 0.60–0.74, P < 0.001), dos comorbilidades (RPA = 0.86, 95 % IC 0.75–0.98, P = 0.0319), y una comorbilidad (RPA = 0.82, 95 % IC 0.73–0.92, P = 0.0008) fueron menos adherentes que aquellos sin comorbilidades. Residentes de áreas rurales (RPA = 0.90, 95 % IC 0.63–0.98, P = 0.0385) y áreas metropolitanas pequeñas (RPA = 0.82, 95 % IC 0.72–0.94, P = 0.0032) fueron menos adherentes que los residentes de grandes áreas metropolitanas. No hubo diferencias raciales en adherencia óptima. Intervenciones enfocadas a proveer apoyo de adherencia, coordinación de servicios y navegación por pares son críticas para alcanzar una adherencia óptima en esta población.

Palabras Clave

VIH/SIDA Adherencia antiretroviral Personas viviendo con VIH Adulto mayor Envejecimiento 


  1. 1.
    Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans: the public health perspective. Am J Public Health. 2012;102(8):1516–26.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. HIV surveillance report. 2014. Accessed 2 Feb 2016.
  3. 3.
    Linley L, Prejean J, An Q, Chen M, Hall IH. Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005–2008. Am J Public Health. 2012;102(8):1527–34.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Navarro G, Nogueras MM, Segura F, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect. 2008;57(1):64–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged ≥50 years compared with younger people in an urban observational cohort. Clin Infect Dis. 2003;36(2):212–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemo. 2006;57(1):4–7.CrossRefGoogle Scholar
  7. 7.
    Abara WE, Smith L, Zhang S, Fairchild AJ, Heiman HJ, Rust G. The influence of race and comorbidity on the timely initiation of antiretroviral therapy among older persons living with HIV/AIDS. Am J Public Health. 2014;104(11):e135–41.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Davis DH, Smith R, Brown A, Rice B, Yin Z, Delpech V. Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age Ageing. 2013;42(4):520–6.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Schick V, Herbenick D, Reece M, et al. Sexual behaviors, condom use, and sexual health of Americans over 50: implications for sexual health promotion for older adults. J Sexual Med. 2010;7(s5):315–29.CrossRefGoogle Scholar
  10. 10.
    Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. New Eng J Med. 2007;357(8):762–74.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Emlet CA. “You’re awfully old to have this disease”: experiences of stigma and ageism in adults 50 years and older living with HIV/AIDS. Gerontologist. 2007;46(6):781–90.CrossRefGoogle Scholar
  12. 12.
    Emlet CA. A comparison of HIV stigma and disclosure patterns between older and younger adults living with HIV/AIDS. AIDS Patient Care STDS. 2006;20(5):350–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Skiest DJ, Rubinstien E, Carley N, Gioiella L, Lyons R. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med. 1996;101(6):605–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Shah SS, McGowan JP, Smith C, Blum S, Klein RS. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis. 2002;35(10):1238–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7(8):549–57.PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson CJ, Heckman TG, Hansen NB, Kochman A, Sikkema KJ. Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models. AIDS Care. 2009;21(5):541–51.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Cohen MS, Chen YQ, McCauley M, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Kong MC, Nahata MC, Lacombe VA, Seiber EE, Balkrishnan R. Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection. J Gen Intern Med. 2012;27(9):1159–64.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalization risk, and other healthcare utilization and costs in a US Medicaid population with HIV. BMJ Open. 2013;3(8):e003028.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Bottonari KA, Tripathi SP, Fortney JC, et al. Correlates of antiretroviral and antidepressant adherence among depressed HIV-infected patients. AIDS Patient Care STDs. 2012;26(5):265–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Reynolds NR, Testa MA, Marc LG, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004;8(2):141–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38(4):432–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(S1):S19–25.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Parsons JT, Starks TJ, Millar BM, Boonrai K, Marcotte D. Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. Drug Alc Depend. 2014;2014(139):33–40.CrossRefGoogle Scholar
  29. 29.
    Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007;26(1):40.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Brañas F, Berenguer J, Sánchez-Conde M, et al. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med. 2008;21(9):820–4.CrossRefGoogle Scholar
  31. 31.
    Bianco JA, Heckman TG, Sutton M, Watakakosol R, Lovejoy T. Predicting adherence to antiretroviral therapy in HIV-infected older adults: the moderating role of gender. AIDS Behav. 2011;15(7):1437–46.PubMedCrossRefGoogle Scholar
  32. 32.
    Simone MJ, Appelbaum J. HIV in older adults. Geriatrics. 2008;63(12):6–12.PubMedGoogle Scholar
  33. 33.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008. p. 1–139. Accessed 10 May 2015.
  34. 34.
    Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.PubMedCrossRefGoogle Scholar
  35. 35.
    Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmaco. 2006;40(7–8):1280–8.CrossRefGoogle Scholar
  37. 37.
    Braithwaite RS, Kozal MJ, Chang CH, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21(12):1579–89.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kong MC, Nahata MC, Lacombe VA, Seiber EE, Balkrishnan R. Association between race, depression, and antiretroviral therapy adherence in a low-income population with HIV infection. J Gen Intern Med. 2012;27(9):1159–64.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18(4):248–57.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Pruitt Z, Robst J, Langland-Orban B, Brooks RG. Healthcare costs associated with antiretroviral adherence among Medicaid patients. App Health Econ Health Policy. 2014;13(1):69–80.CrossRefGoogle Scholar
  42. 42.
    Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8(4):277–87.PubMedCrossRefGoogle Scholar
  43. 43.
    Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17(5):558–65.PubMedCrossRefGoogle Scholar
  44. 44.
    Cantudo-Cuenca MR, Jiménez-Galán R, Almeida-González CV, Morillo-Verdugo R. Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J Manag Care Pharm. 2014;20(8):844–50.Google Scholar
  45. 45.
    Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28(10):1302–10.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging. 2008;3(3):453–72.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Monroe AK, Rowe TL, Moore RD, Chander G. Medication adherence in HIV-positive patients with diabetes or hypertension: a focus group study. BMC Health Serv Res. 2013;13(1):488.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Prefer Adherence. 2012;6:297–322.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Henderson KC, Hindman J, Johnson SC, Valuck RJ, Kiser JJ. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care STDs. 2011;25(4):221–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist’s interventions. AIDS Care. 2010;22(10):1189–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Abara W, Heiman HJ. The Affordable Care Act and low-income people living with HIV: looking forward in 2014 and beyond. J Assoc Nurses AIDS Care: JANAC. 2014;25(6):476–82.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Cahill SR, Mayer KH, Boswell SL. The Ryan White HIV/AIDS program in the age of health care reform. Am J Public Health. 2015;105(6):1078–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Winston E. Abara
    • 1
  • Oluwatoyosi A. Adekeye
    • 1
  • Junjun Xu
    • 2
  • Harry J. Heiman
    • 3
  • George Rust
    • 2
  1. 1.Department of Community Health and Preventive Medicine, Satcher Health Leadership InstituteMorehouse School of MedicineAtlantaUSA
  2. 2.National Center for Primary CareMorehouse School of MedicineAtlantaUSA
  3. 3.Satcher Health Leadership InstituteMorehouse School of MedicineAtlantaUSA

Personalised recommendations